Your browser is no longer supported. Please, upgrade your browser.
Settings
PBYI Puma Biotechnology, Inc. daily Stock Chart
PBYI [NASD]
Puma Biotechnology, Inc.
Index- P/E- EPS (ttm)-2.61 Insider Own11.20% Shs Outstand39.29M Perf Week-6.87%
Market Cap607.03M Forward P/E- EPS next Y-0.43 Insider Trans-0.54% Shs Float33.44M Perf Month-54.03%
Income-99.30M PEG- EPS next Q-0.17 Inst Own90.90% Short Float13.00% Perf Quarter-46.00%
Sales283.50M P/S2.14 EPS this Y61.90% Inst Trans-2.81% Short Ratio3.39 Perf Half Y-33.20%
Book/sh1.13 P/B13.67 EPS next Y102.00% ROA-37.90% Target Price25.50 Perf Year-69.68%
Cash/sh3.83 P/C4.04 EPS next 5Y- ROE-245.20% 52W Range15.07 - 65.45 Perf YTD-24.08%
Dividend- P/FCF- EPS past 5Y-9.50% ROI-55.70% 52W High-76.39% Beta0.82
Dividend %- Quick Ratio2.50 Sales past 5Y- Gross Margin87.20% 52W Low2.52% ATR1.59
Employees272 Current Ratio2.50 Sales Q/Q49.00% Oper. Margin-30.60% RSI (14)16.30 Volatility5.58% 5.85%
OptionableYes Debt/Eq3.51 EPS Q/Q59.40% Profit Margin-35.00% Rel Volume0.60 Prev Close15.30
ShortableYes LT Debt/Eq3.51 EarningsMay 09 AMC Payout- Avg Volume1.28M Price15.45
Recom3.30 SMA20-35.96% SMA50-51.03% SMA200-52.98% Volume764,885 Change0.98%
May-10-19Downgrade Citigroup Buy → Neutral $24
May-10-19Downgrade Cantor Fitzgerald Overweight → Neutral $57 → $20
Jan-17-19Initiated Leerink Partners Mkt Perform $21
Jan-03-19Downgrade Guggenheim Buy → Neutral
Nov-19-18Upgrade Goldman Sell → Neutral
Nov-02-18Downgrade JP Morgan Neutral → Underweight
Nov-02-18Downgrade BofA/Merrill Buy → Underperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $75
Sep-17-18Initiated Goldman Sell $42
May-11-18Reiterated Stifel Buy $95 → $87
Nov-10-17Reiterated RBC Capital Mkts Sector Perform $92 → $108
Nov-10-17Reiterated Citigroup Buy $156 → $164
Oct-02-17Reiterated Stifel Buy $110 → $130
Sep-11-17Reiterated Credit Suisse Outperform $118 → $136
Jul-10-17Resumed Leerink Partners Outperform $115
Jun-06-17Reiterated RBC Capital Mkts Sector Perform $60 → $88
May-25-17Reiterated RBC Capital Mkts Sector Perform $40 → $60
Mar-02-17Reiterated RBC Capital Mkts Sector Perform $48 → $17
Sep-22-16Reiterated Credit Suisse Outperform $54 → $111
Sep-21-16Upgrade Stifel Hold → Buy $61 → $88
May-18-19 12:00PM  Investors Are Right to Worry About Puma Biotechnology Motley Fool
May-14-19 07:30AM  Jim Cramer Gives His Opinion On Becton Dickinson, Fox, Puma Biotech And More Benzinga
May-10-19 04:46PM  Biotech Hammered On 'Shockingly Poor' Report For Breast Cancer Drug Investor's Business Daily -38.64%
02:38PM  Here's Why Puma Biotechnology Fell as Much as 40.7% Today Motley Fool
10:53AM  Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales TheStreet.com
10:17AM  Puma Biotech Shares Plunge After Nerlynx Update, Quarterly Report Benzinga
10:00AM  Puma Biotech (PBYI) Q1 Earnings Top, Nerlynx Disappoints Zacks
07:24AM  Puma Biotechnology Inc (PBYI) Q1 2019 Earnings Call Transcript Motley Fool
01:50AM  Edited Transcript of PBYI earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-09-19 07:25PM  Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates Zacks
06:24PM  Puma Biotech: 1Q Earnings Snapshot Associated Press
05:40PM  Puma Bio down 33% as more patients forgoing treatment with its cancer drug MarketWatch
04:10PM  Puma Biotechnology Reports First Quarter 2019 Financial Results Business Wire
12:17PM  Here's Why Puma Biotechnology Fell 17.2% in April Motley Fool
May-08-19 04:25PM  Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019 Business Wire
May-05-19 05:53PM  Did Hedge Funds Drop The Ball On Puma Biotechnology Inc (PBYI)? Insider Monkey
May-03-19 04:20PM  Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-02-19 10:33AM  Analysts Estimate Puma Biotech (PBYI) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-25-19 04:20PM  Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Business Wire
Apr-18-19 03:01PM  Should You Worry About Puma Biotechnology, Inc.'s (NASDAQ:PBYI) CEO Pay? Simply Wall St.
Apr-09-19 07:16PM  Here's Why Puma Biotechnology Rose 39.5% in March Motley Fool
05:05PM  Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Apr-05-19 09:29AM  Puma Biotech Adds Two Cohorts to Nerlynx Label Expansion Study Zacks
Apr-04-19 08:30AM  Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations Business Wire
Apr-02-19 10:45AM  Puma Biotech Out-Licenses Nerlynx Rights in Europe, Stock Down Zacks
Apr-01-19 05:13PM  Here's Why Puma Biotechnology Tumbled on Monday Motley Fool -8.12%
02:36PM  Options Volume Spikes on Sinking Drug Stock Schaeffer's Investment Research
09:25AM  The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage Zacks
08:00AM  Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe Business Wire
Mar-30-19 09:30AM  Why Is Puma Biotech (PBYI) Up 39.5% Since Last Earnings Report? Zacks
Mar-28-19 08:30AM  Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019 Business Wire
Mar-19-19 05:53PM  Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia Zacks -5.26%
Mar-18-19 04:31PM  Why Edwards Lifesciences, Village Farms International, and Puma Biotechnology Jumped Today Motley Fool +8.17%
03:45PM  Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting Business Wire
08:45AM  Puma Biotechnologys Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Business Wire
Mar-15-19 12:08AM  Edited Transcript of PBYI earnings conference call or presentation 28-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-14-19 04:30PM  Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire -6.50%
11:20AM  Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why Zacks
Mar-08-19 05:55AM  Will Puma Biotechnology Continue to Surge Higher? Zacks
Mar-05-19 04:15PM  Puma Biotechnology to Present at Cowens Annual Health Care Conference Business Wire
08:58AM  Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options Zacks
Mar-04-19 05:27PM  3 Takeaways from Puma Biotechnology's 2018 Earnings Motley Fool
07:50AM  Recent Analysis Shows Altria Group, Puma Biotechnology, Tanger Factory Outlet Centers, PTC, Aptiv, and Olin Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-01-19 12:58PM  Puma Biotechnology Earnings: PBYI Stock Skyrockets on Q4 Results InvestorPlace +39.99%
11:23AM  Cantor Fitzgerald Bumps Puma Biotechnology Price Target On Strong Nerlynx Sales Benzinga
11:19AM  Here's Why Puma Biotechnology Is Soaring Today Motley Fool
10:17AM  Puma Biotech (PBYI) Q4 Loss Narrows, Nerlynx Pulls Stock Up Zacks
08:50AM  The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis Benzinga
Feb-28-19 09:35PM  Puma Biotechnology Inc (PBYI) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:09PM  Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire
09:12AM  Puma Biotechnology Q4 Earnings Preview Benzinga
09:00AM  Predictive Technology Group Names Jay M. Moyes to Its Board of Directors GlobeNewswire
Feb-26-19 09:20PM  Celcuity Inc. (CELC) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-21-19 10:31AM  Puma Biotech (PBYI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Feb-15-19 04:20PM  Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-14-19 12:58PM  5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings Zacks
Feb-13-19 04:20PM  Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results Business Wire
Feb-06-19 12:47PM  Need To Know: Puma Biotechnology, Inc. (NASDAQ:PBYI) Insiders Have Been Selling Shares Simply Wall St.
Feb-04-19 09:54PM  Puma Biotechnology Announces Litigation Victory with Jurys Decision Business Wire
Jan-22-19 11:02AM  Is Puma Biotechnology a Buy? Motley Fool -6.11%
Jan-17-19 07:45AM  Detailed Research: Economic Perspectives on Delta Air Lines, Duke Energy, Fiserv, The Chefs' Warehouse, Maxim Integrated Products, and Puma Biotechnology What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jan-11-19 10:38AM  Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why Zacks -6.44%
08:03AM  Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada Business Wire
08:00AM  Knight Therapeutics Runs with Exclusive Canadian License to Pumas NERLYNX® GlobeNewswire
Jan-10-19 03:19PM  Athenex Completes Enrollment Target for Breast Cancer Study Zacks +5.35%
Jan-03-19 04:20PM  Puma Biotechnology to Present at J. P. Morgan Healthcare Conference Business Wire
Jan-02-19 04:50PM  Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire +6.54%
Dec-18-18 11:10AM  A Bull And Bear Review Positive Results For Puma Biotech's Late-Stage Breast Cancer Drug Trial Benzinga
10:20AM  Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer Zacks
08:00AM  The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan Benzinga
07:00AM  Today's Research Reports on Trending Tickers: Puma Biotechnology and FibroGen ACCESSWIRE
Dec-17-18 04:31PM  Puma Bio stock rises more than 9% on drug study MarketWatch -5.14%
04:05PM  Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer Business Wire
Dec-14-18 03:17AM  Puma Biotechnology Inc (PBYI): Hedge Fund Sentiment Unchanged Insider Monkey
Dec-12-18 08:19AM  3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019 Motley Fool
08:10AM  Investor Expectations to Drive Momentum within CatchMark Timber Trust, Edison International, Puma Biotechnology, Maxim Integrated Products, Wabash National, and Resolute Energy Discovering Underlying Factors of Influence GlobeNewswire
Dec-11-18 05:56PM  Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-10-18 04:35PM  Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-06-18 05:14PM  Here's Why Puma Biotechnology Tanked 37.3% in November Motley Fool
08:00AM  Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium Business Wire
08:00AM  Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium Business Wire
08:00AM  Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium Business Wire
Dec-03-18 04:20PM  Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-16-18 07:47AM  Edited Transcript of PBYI earnings conference call or presentation 1-Nov-18 8:30pm GMT Thomson Reuters StreetEvents
Nov-09-18 08:20AM  Investor Expectations to Drive Momentum within Matson, Craft Brew Alliance, Easterly Government Properties, Novanta, Ascena Retail Group, and Puma Biotechnology Discovering Underlying Factors of Influence GlobeNewswire
Nov-07-18 04:15PM  Puma Biotechnology to Present at Credit Suisse Healthcare Conference Business Wire
09:30AM  Biotech Stocks and the Midterm Elections ACCESSWIRE
Nov-05-18 10:25AM  Puma Biotech (PBYI) Q3 Loss Narrows, Nerlynx Pulls Stock Down Zacks +13.90%
Nov-02-18 01:47PM  Here's Why Puma Biotechnology Inc. Is Getting Hammered Today Motley Fool -48.01%
08:52AM  Puma Biotechnology's stock plunges to pace premarket losers after key drug Nerlynx disappoints MarketWatch
Nov-01-18 08:45PM  Puma Biotech (PBYI) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:42PM  Puma Biotech: 3Q Earnings Snapshot Associated Press
05:56PM  Why Puma Biotechnology, Inc. Stock Is Getting Crushed Today Motley Fool
04:10PM  Puma Biotechnology Reports Third Quarter 2018 Financial Results Business Wire
Oct-25-18 10:34AM  Puma Biotech (PBYI) Q3 Earnings Preview: What to Look Out For Zacks
Oct-18-18 04:15PM  Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Business Wire
11:37AM  Puma Biotech (PBYI) Rides High on Robust Nerlynx Performance Zacks
Oct-17-18 07:20AM  Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis Discovering Underlying Factors of Influence GlobeNewswire
Oct-16-18 05:51PM  Celcuity Announces Clinical Trial Collaboration with Puma Biotechnology and West Cancer Center Business Wire
Oct-10-18 05:00PM  Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BRYCE RICHARD PAULSEE REMARKSMay 02Sale32.38852,75238,924May 06 04:39 PM
AUERBACH ALAN HPRESIDENT AND CEOMay 02Sale32.3847715,4454,203,218May 06 04:37 PM
BRYCE RICHARD PAULSEE REMARKSApr 02Sale35.78883,14939,009Apr 03 05:00 PM
AUERBACH ALAN HPRESIDENT AND CEOApr 02Sale35.7949117,5734,203,695Apr 03 04:58 PM
BRYCE RICHARD PAULSEE REMARKSMar 04Sale38.66883,40239,097Mar 22 04:53 PM
AUERBACH ALAN HPRESIDENT AND CEOMar 04Sale38.6249619,1564,204,186Mar 22 04:51 PM
EYLER CHARLES RSEE REMARKSFeb 04Sale27.64872,40531,957Feb 06 04:38 PM
BRYCE RICHARD PAULSEE REMARKSFeb 04Sale27.77892,47229,285Feb 06 04:34 PM
AUERBACH ALAN HPRESIDENT AND CEOFeb 04Sale27.803459,5914,165,467Feb 06 04:30 PM
Lo StevenChief Commercial OfficerJan 22Sale24.912,11452,66421,409Jan 24 04:54 PM
EYLER CHARLES RSEE REMARKSJan 22Sale24.8071317,68232,044Jan 24 04:51 PM
BRYCE RICHARD PAULSEE REMARKSJan 22Sale24.721,95948,42629,374Jan 24 04:47 PM
AUERBACH ALAN HPRESIDENT AND CEOJan 22Sale24.748,825218,3344,165,812Jan 24 04:44 PM
AUERBACH ALAN HPRESIDENT AND CEOJan 03Sale20.674,42491,4444,174,637Jan 04 06:26 PM
EYLER CHARLES RSEE REMARKSJan 03Sale20.671,21025,01132,757Jan 04 05:16 PM
BRYCE RICHARD PAULSEE REMARKSJan 03Sale20.671,21025,01131,333Jan 04 05:08 PM
EYLER CHARLES RSEE REMARKSDec 03Sale22.771,23928,21233,967Dec 04 04:59 PM
Lo StevenChief Commercial OfficerJul 20Sale51.851,83995,36023,523Jul 24 05:10 PM
EYLER CHARLES RSEE REMARKSJul 20Sale51.9561031,69035,206Jul 24 05:07 PM
BRYCE RICHARD PAULSEE REMARKSJul 20Sale51.951,83695,38132,543Jul 24 05:03 PM
AUERBACH ALAN HPRESIDENT AND CEOJul 20Sale52.0012,520651,0204,179,061Jul 24 05:00 PM
EYLER CHARLES RSEE REMARKSJun 01Sale53.001,21164,18335,816Jun 04 05:08 PM